Difficulty: Intermediate | Prerequisites: Basic autonomic nervous system pharmacology, understanding of intraocular pressure (IOP) and glaucoma types
Glaucoma is a leading cause of irreversible blindness worldwide, and the primary modifiable risk factor is elevated intraocular pressure (IOP). These three drug classes, beta-adrenergic blockers, cholinergic agonists, and cholinesterase inhibitors, are all topical ophthalmic medications used to lower IOP and slow disease progression. They work through different autonomic pathways, so understanding the ANS is essential before diving in. This topic sits at the intersection of autonomic pharmacology and ophthalmic nursing care: you need to know not just how the drugs work, but how to administer them safely, what systemic side effects to watch for, and what to teach clients.
Beta blockers (betaxolol, timolol), cholinergic agonists (pilocarpine), and cholinesterase inhibitors (echothiophate) are all eye drops that lower intraocular pressure in glaucoma. They each carry the risk of systemic absorption, so proper instillation technique (pressing on the puncta for 60 seconds) is critical. The exam loves to test contraindications, systemic side effects, and client teaching points for each drug.
Intraocular pressure (IOP)
The fluid pressure inside the eye. Elevated IOP is the main modifiable risk factor for glaucoma. Think of it as the pressure building up because fluid (aqueous humour) is not draining properly.
Beta-adrenergic blocker (ophthalmic)
A drug that blocks beta receptors in the eye, reducing production of aqueous humour and thereby lowering IOP. In simple terms, it turns down the tap on the fluid your eye makes.
Cholinergic agonist
A drug that mimics acetylcholine at muscarinic receptors in the eye, causing pupil constriction (miosis) and opening the trabecular meshwork to improve aqueous humour outflow. Think of it as pulling open the drain so fluid leaves the eye more easily.
Cholinesterase inhibitor (ophthalmic)
A drug that blocks the enzyme acetylcholinesterase, allowing acetylcholine to accumulate at the receptor and prolong its effect. In simple terms, instead of adding more acetylcholine, it stops the body from breaking down what is already there.
Miosis
Constriction (narrowing) of the pupil. This is the mechanism by which cholinergic agents open the drainage angle in the eye. The opposite of mydriasis (dilation).
Nasolacrimal occlusion (punctal occlusion)
The technique of pressing gently on the inner corner of the eye (over the puncta and nasolacrimal sac) after instilling eye drops to prevent the drug from draining into the nasal passages and entering the systemic circulation. This is the single most important administration step for all of these drops.
Betaxolol
A cardioselective (beta-1 selective) ophthalmic beta blocker. Because it is relatively selective, it is somewhat safer in patients with mild airway disease, though caution is still required.
Timolol
A non-selective ophthalmic beta blocker (blocks both beta-1 and beta-2 receptors). Effective at lowering IOP but carries greater risk of bronchospasm, making it contraindicated in asthma and COPD.
Pilocarpine
A direct-acting cholinergic agonist used topically to treat glaucoma. The classic miotic agent. Commonly causes decreased visual acuity (especially at night) and headache.
Echothiophate
An irreversible cholinesterase inhibitor used as an ophthalmic drop. Because it is irreversible, its effects are long-lasting, and it carries the risk of cataract formation with prolonged use.
Tags: beta blocker eye drops, timolol glaucoma, betaxolol glaucoma, ophthalmic beta blockers
Topical therapy to lower IOP in chronic open-angle glaucoma and acute closed-angle glaucoma
Block beta-adrenergic receptors in the ciliary body, reducing production of aqueous humour
Result: less fluid produced, IOP falls
Local effects: stinging, burning, and eye discomfort on instillation
Systemic cardiac effects: bradycardia, hypotension (the drug can be absorbed systemically through the nasolacrimal duct)
Systemic respiratory effects: bronchospasm (especially with non-selective agents like timolol)
Betaxolol: heart block, bradycardia, cardiogenic shock
Timolol: heart block, heart failure, COPD, asthma, acute bronchospasm
Betaxolol: concurrent use of systemic beta blockers (additive effects), airway disorders
Timolol: liver or renal disorders, hyperthyroidism, cerebrovascular disease or stroke, older adults, myasthenia gravis
Concurrent use with systemic beta blockers causes increased systemic effects (additive bradycardia, hypotension)
Calcium channel blockers can also increase systemic effects when combined with ophthalmic beta blockers
Tags: pilocarpine eye drops, echothiophate glaucoma, cholinergic agonist eye drops, miotic agents, cholinesterase inhibitor ophthalmic
Topical therapy to lower IOP in glaucoma
Adjunct to laser and other eye surgeries and procedures
Pilocarpine (direct-acting cholinergic agonist): stimulates muscarinic receptors in the iris sphincter and ciliary muscle, causing miosis and contraction of the ciliary muscle, which opens the trabecular meshwork and improves aqueous humour outflow
Echothiophate (irreversible cholinesterase inhibitor): prevents breakdown of acetylcholine at the neuromuscular junction in the eye, producing prolonged miosis and the same drainage-enhancing effect
Cholinergic systemic effects (both drugs): urinary urgency, bradycardia, constriction of the bronchioles
Pilocarpine-specific: decreased visual acuity (especially at night), headache (more common in younger clients, may subside with time), risk of retinal detachment
Echothiophate-specific: decreased visual acuity (especially at night), development of cataracts with prolonged use
Pilocarpine: acute inflammatory eye disorders (the miosis and increased vascular permeability would worsen inflammation)
Echothiophate: history of retinal detachment
Pilocarpine: chronic respiratory disorders, hypertension, gallbladder disease
Echothiophate: cardiac or chronic respiratory disease, hyperthyroidism, urinary tract blockage, Parkinson's disease
Pilocarpine: antagonises the effect of anticholinergic drugs (they work in opposite directions at muscarinic receptors, so giving both cancels out the benefit)
Echothiophate: organophosphates used in gardening (insecticides) may increase effects of the drug, because organophosphates are also cholinesterase inhibitors
Tags: eye drop administration technique, nasolacrimal occlusion, punctal pressure, ophthalmic drug administration nursing
Hold gentle pressure on the puncta and nasolacrimal sac for at least 60 seconds immediately after instillation to minimise systemic absorption
Do not touch or drop the eye dropper (contamination risk)
When instilling for a client: apply clean gloves, instruct client to wash hands
Do not apply with contact lenses in place
Administer in the evening
Space at least 5 minutes apart from other eye drops
Monitor vital signs (watching for bradycardia, hypotension, respiratory changes)
Administer a mild analgesic for headache that does not resolve shortly after drug administration
Implement safety measures for nighttime ambulation (visual acuity is reduced, especially at night)
Monitor for symptoms of retinal detachment (dark floaters, flashes of light, "curtain" effect over vision)
Observe for opacity behind the pupil when shining a penlight into the eye (sign of cataract development with echothiophate), and report findings to the provider
Tags: patient teaching glaucoma eye drops, client education ophthalmic medications
Advise the client that local effects (stinging, burning) are transitory after application; the client should not rub their eyes
Instruct on correct instillation technique to minimise systemic effects (punctal occlusion for 60 seconds)
Instruct the client to report to their provider: slow pulse, fainting spells, wheezing, urinary urgency, slow heart rate
Instruct the client to report decreased visual acuity and headache to their provider
Advise the client to avoid driving (especially at night) and other activities requiring good visual acuity if vision is affected
Teach the client to recognise symptoms of retinal detachment: dark floaters, flashes of light, a feeling as if a "curtain" has been pulled over part of vision in one eye
Instruct the client to report any decrease in both daytime and nighttime vision to their provider
These drugs are a frontline treatment for glaucoma in clinical practice. A community nurse visiting an elderly client at home will routinely need to check that they are instilling their timolol or pilocarpine drops correctly and applying punctal pressure, because poor technique is one of the most common reasons for uncontrolled IOP.
The organophosphate interaction with echothiophate is a practical consideration for clients who garden: exposure to common insecticide sprays can potentiate the drug's cholinergic effects and trigger a systemic reaction.
"Ophthalmic drops only affect the eye." They do not. All of these drugs can be absorbed systemically through the nasolacrimal duct, which is why punctal occlusion and vital sign monitoring matter.
"Betaxolol and timolol are interchangeable." They are not. Timolol is non-selective (blocks beta-1 and beta-2), making it contraindicated in asthma and COPD. Betaxolol is beta-1 selective and somewhat safer for airway patients, though still used with caution.
"Pilocarpine and echothiophate do the same thing in the same way." They share the same end effect (prolonged miosis), but pilocarpine directly stimulates the muscarinic receptor, while echothiophate works indirectly by blocking the enzyme that breaks down acetylcholine. Echothiophate is irreversible, which is why its effects last longer and it carries a cataract risk.
"Headache from pilocarpine means the drug should be stopped." Not necessarily. Headache is a common early side effect, particularly in younger clients, and often subsides with continued use. A mild analgesic can be given. Only persistent or severe headache warrants reporting to the provider.
⚠️ Punctal occlusion technique is heavily tested. Know the 60-second rule and why it matters (prevents systemic absorption).
⚠️ Contraindications are a favourite exam topic. Timolol + asthma/COPD = contraindicated. Echothiophate + history of retinal detachment = contraindicated. Pilocarpine + acute inflammatory eye disorder = contraindicated.
⚠️ Systemic side effects from topical eye drops trip students up. Be ready to identify bradycardia, hypotension, and bronchospasm as signs of systemic beta blocker absorption, and urinary urgency, bradycardia, and bronchiole constriction as cholinergic systemic effects.
⚠️ Retinal detachment signs (floaters, flashes, curtain effect) are high-yield for NCLEX-style questions.
⚠️ Contact lenses must be removed before instilling any of these drops.
⚠️ Echothiophate administration timing: evening dosing, at least 5 minutes apart from other drops.
True or false: Timolol is safe to use in a client with asthma.
False. Timolol is a non-selective beta blocker and is contraindicated in asthma and COPD due to risk of bronchospasm.
After instilling any ophthalmic drop from this group, you should apply pressure to the ______ and ______ for at least ______ seconds.
Puncta and nasolacrimal sac for at least 60 seconds.
True or false: Echothiophate should be administered in the morning.
False. Echothiophate is administered in the evening.
A client on pilocarpine reports seeing dark floaters and flashes of light. What condition should you suspect?
Retinal detachment.
True or false: Contact lenses may remain in place during instillation of these eye drops.
False. Contact lenses must be removed before instillation.
Q: A client with chronic open-angle glaucoma is prescribed timolol eye drops. Which finding in the client's history should the nurse report to the provider before administering the first dose?
A: A history of COPD or asthma. Timolol is a non-selective beta blocker and is contraindicated in clients with obstructive airway disease because systemic absorption can cause bronchospasm.
Q: The nurse is teaching a client about pilocarpine eye drops. What adverse effects should the client be instructed to report?
A: Decreased visual acuity (especially at night), persistent headache, and any signs of retinal detachment (dark floaters, flashes of light, "curtain" over part of vision in one eye).
Q: Why does the nurse instruct the client to press on the inner corner of the eye after instilling ophthalmic beta blockers?
A: Pressing on the puncta and nasolacrimal sac (nasolacrimal occlusion) for at least 60 seconds prevents the drug from draining through the nasolacrimal duct into the nasal mucosa and being absorbed systemically, reducing the risk of systemic side effects such as bradycardia, hypotension, and bronchospasm.
Q: A client on echothiophate eye drops mentions they have been using an organophosphate insecticide in their garden. What is the nurse's concern?
A: Organophosphates are also cholinesterase inhibitors. Combined exposure can potentiate the cholinergic effects of echothiophate, increasing the risk of systemic toxicity (bradycardia, bronchospasm, urinary urgency). The nurse should advise the client to avoid organophosphate exposure and report this to the provider.
Q: A nurse is assessing a client who has been taking echothiophate for several months. When shining a penlight into the eye, the nurse observes opacity behind the pupil. What does this suggest, and what action should the nurse take?
A: Opacity behind the pupil suggests cataract development, a known adverse effect of long-term echothiophate use. The nurse should report this finding to the provider.
This material connects directly to autonomic nervous system pharmacology: the same sympathetic/parasympathetic principles that govern systemic beta blockers and cholinergic drugs apply here, just in a topical ophthalmic context. If you understand why propranolol causes bradycardia, you understand why timolol eye drops can do the same.
It also links to glaucoma pathophysiology (aqueous humour dynamics, trabecular meshwork drainage) and to broader nursing assessment skills, particularly recognising retinal detachment and performing a focused eye assessment.
For the pharmacology course overall, this topic pairs well with other IOP-lowering drug classes you may encounter later, such as prostaglandin analogues (latanoprost), alpha-2 agonists (brimonidine), and carbonic anhydrase inhibitors (dorzolamide).
Glaucoma eye drops, IOP-lowering medications, ophthalmic beta blockers, timolol maleate, betaxolol HCl, pilocarpine hydrochloride, echothiophate iodide, miotic agents, cholinergic agonist eye drops, cholinesterase inhibitor ophthalmic, nasolacrimal occlusion, punctal pressure technique, open-angle glaucoma pharmacology, closed-angle glaucoma treatment, retinal detachment signs, NCLEX pharmacology glaucoma, nursing interventions eye drops, systemic absorption ophthalmic drugs, autonomic pharmacology eye